Literature DB >> 7795044

Bacterial vaccine vectors and bacillus Calmette-Guérin.

J D Cirillo1, C K Stover, B R Bloom, W R Jacobs, R G Barletta.   

Abstract

Recent advances in biotechnology now allow a more modern approach to the development of vaccines, particularly that of recombinant vaccines. Bacterial vaccine vectors have the advantage over viral vectors in that the former have the ability to express a greater number of antigens in different forms. Although no recombinant bacterial vaccines are currently in use, bacillus Calmette-Guérin (BCG), Salmonella species, and Escherichia coli are being developed as vaccine vectors. We review plasmid systems and mutant strains developed for the expression of foreign antigens, with particular emphasis on those developed for BCG. We describe the development of antigen expression systems as well as the immune response elicited by recombinant BCG vaccine strains to bacterial and human immunodeficiency virus (HIV) antigens. A modified recombinant BCG carrier with selection for the stable maintenance of rDNA is proposed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795044     DOI: 10.1093/clinids/20.4.1001

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine.

Authors:  N B Harris; R G Barletta
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

Review 2.  Genetic vaccination against tuberculosis.

Authors:  D B Lowrie; C L Silva; R E Tascon
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

4.  Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses.

Authors:  R Vemulapalli; Y He; S M Boyle; N Sriranganathan; G G Schurig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

5.  Immunogenicity and reactivity of novel Mycobacterium avium subsp. paratuberculosis PPE MAP1152 and conserved MAP1156 proteins with sera from experimentally and naturally infected animals.

Authors:  John P Bannantine; Avery L Paulson; Ofelia Chacon; Robert J Fenton; Denise K Zinniel; David S McVey; David R Smith; Charles J Czuprynski; Raúl G Barletta
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

6.  Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.

Authors:  Joan Joseph; Raquel Fernández-Lloris; Elías Pezzat; Narcís Saubi; Pere-Joan Cardona; Beatriz Mothe; Josep Maria Gatell
Journal:  J Biomed Biotechnol       Date:  2010-06-27

7.  Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.

Authors:  Rosamund Chapman; Enid Shephard; Helen Stutz; Nicola Douglass; Vasan Sambandamurthy; Irene Garcia; Bernhard Ryffel; William Jacobs; Anna-Lise Williamson
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 8.  Adenoviruses as vectors for delivering vaccines to mucosal surfaces.

Authors:  L A Babiuk; S K Tikoo
Journal:  J Biotechnol       Date:  2000-09-29       Impact factor: 3.307

Review 9.  Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis.

Authors:  Reginaldo G Bastos; Heba F Alzan; Vignesh A Rathinasamy; Brian M Cooke; Odir A Dellagostin; Raúl G Barletta; Carlos E Suarez
Journal:  Vaccines (Basel)       Date:  2022-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.